UK-based Crescendo Biologics Ltd has secured its first commercial deal since its founding in 2007 with the signing of a collaboration and license option agreement with Takeda Pharmaceutical Company Ltd. The deal concerns several preclinical drug candidates that have been derived from the VH antibody domains of transgenic mice.
